# Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

> **NCT05371496** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Mayo Clinic** · enrollment: 81 (estimated)

## Conditions studied

- Cardiomyopathy
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo
- **BEHAVIORAL:** Counselling on healthy lifestyle intervention

## Key facts

- **NCT ID:** NCT05371496
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-09-06
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05371496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05371496, "Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05371496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*